Enduring Growth Potential

enduring_growth_potential

The digital pathology market was valued at USD882.7 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 6.8% from 2021 to 2028, according to Grand View Research.

Parasitology is an extremely important field within diagnostics and pathology. Millions of parasitology tests are conducted on humans each year, and approximately €275 million is currently spent on faecal egg tests in veterinary practices on an annual basis. As a result, digital parasitology has incredible global appeal, and technologies such as OvaCyte™ are on-trend and increasingly in demand.

With agricultural intensification and a growing population, Telenostic is paving the way for a more seamless, efficient, affordable and accurate way to diagnose parasites in animal and human hosts – no laboratories required.

With their novel AI algorithms and cloud interface capability, Telenostic technologies have the potential to be integrated and deployed into every veterinarian practice across the world, as well as on farms, at breeding facilities and in hospitals.

comp-Image1-5

Currently in use in equine, our scalable platform technology, OvaCyte™ is extendable to a wide range of host species including companion animals, bovine, ovine, caprine, porcine, avian and humans. It also has possibilities for environmental application, further broadening the growth trajectory of this revolutionary proprietary technology.

Our leading-edge technologies are founded on extensive research and development, with our first white paper published in 2020 and another to be published in late 2021, co-authored by two world-renowned researchers in equine parasitology.

Telenostic was co-founded by Clare Hughes – who has a history of founding and running successful start-ups in the veterinary space – and Trish McOwan, who is an engineer and has a pedigree of taking product to market.

Further increasing Telenostic’s appeal, OvaCyte™ has limited competitors to contend with. Our primary competitors are laboratories undertaking traditional parasite diagnostics, and they cannot deliver our efficiency, cost-savings or convenience of results. OvaCyte™ is independently validated to meet all current standard laboratory equivalents, methods and sensitivities, delivering results in minutes.

Thanks to OvaCyte™’s aggregated geographical data and herd-specific records, the technology has even greater applications. It may be able to assist departmental bodies in the monitoring of disease outbreak, parasite presence and resistance patterns to maintain best practice animal health, welfare and scientific strategies.

OvaCyte™ itself is also extremely cost effective, ensuring widespread uptake among veterinarians and farmers, who have long had to settle for labour-intensive and time-consuming laboratory testing.